Shanghai Reseat Medical Technology Acquires 16% Stake of U.S. Bionic Eye Technologies
This article was originally published in PharmAsia News
Executive Summary
Hainan Haiyao announced that its subsidiary, Shanghai Reseat Medical Technology, invested and acquired 16% stake of U.S. Bionic Eye Technologies by spending no more than $3 million.